• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Metsera Inc.

    3/10/25 4:06:06 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTSR alert in real time by email
    8-K
    false 0002040807 0002040807 2025-03-07 2025-03-07

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): March 7, 2025

     

     

    METSERA, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-42489   92-0931552

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    3 World Trade Center

    175 Greenwich Street

    New York, New York

      10007
    (Address of principal executive offices)   (Zip Code)

    (212) 784-6595

    (Registrant’s telephone number, include area code)

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbols

     

    Name of each exchange

    on which registered

    Common Stock, $0.00001 par value per share   MTSR   The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.02.

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On March 7, 2025, the Board of Directors of Metsera, Inc. (the “Company”) approved 2024 annual cash bonuses to the Company’s named executive officers for the year ended December 31, 2024 (the “Named Executive Officers”) at 100% of each individual’s target annual bonus based on the Company’s performance for 2024.

    The other compensation for the Named Executive Officers for the year ended December 31, 2024 was previously reported by the Company in the Summary Compensation Table included in the Company’s prospectus filed with the Securities and Exchange Commission on January 31, 2025 pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Prospectus”), relating to the Company’s Registration Statement on Form S-1 (No. 333-284225). However, as of the date of the Prospectus, 2024 annual cash bonuses for the Named Executive Officers had not yet been determined, and therefore such bonus amounts were omitted from the Summary Compensation Table for 2024.

    The table below updates the previously reported Summary Compensation Table by reflecting the annual cash bonuses paid to each Named Executive Officer with respect to 2024, and restating each Named Executive Officer’s total compensation amount for 2024.

     

    Name and Principal Position

       Year      Bonus ($)      Total ($)  

    Christopher Whitten Bernard(3)

    President and Chief Executive Officer

         2024        241,644        5,969,222  

    Clive A. Meanwell, M.B., Ch.B., M.D.(4)

    Executive Chairman and former Chief Executive Officer

         2024        59,836        1,859,617  

    Christopher Visioli(5)

    Chief Financial Officer, Chief Business Officer

         2024        190,000        3,039,019  

    Brian Hubbard, Ph.D.

    Chief Scientific Officer

         2024        181,430        1,196,932  

    Gbola Amusa, M.D.(6)

    Former Chief Financial Officer

         2024        133,336        1,752,153  


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        METSERA, INC.
    Date: March 10, 2025     By:  

    /s/ Christopher Whitten Bernard

          Christopher Whitten Bernard
          President and Chief Executive Officer
    Get the next $MTSR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTSR

    DatePrice TargetRatingAnalyst
    2/25/2025$56.00Buy
    Guggenheim
    2/25/2025$38.00Buy
    BofA Securities
    2/25/2025Outperform
    Evercore ISI
    More analyst ratings

    $MTSR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

      NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11 at 10:00 – 10:35 A.M. EDT. A live webcast and replay of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines

      6/10/25 7:00:39 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

      Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placeb

      6/9/25 7:00:00 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

      Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i, at the 85th Scientif

      6/5/25 7:30:18 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Pinto Joshua

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:42:42 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Chairman Meanwell Clive

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:40:27 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Burow Kristina

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:39:32 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Burow Kristina converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:15:35 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berns Paul L bought $14,219,964 worth of shares (789,998 units at $18.00) and converted options into 7,523,682 shares (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:04:05 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Arch Venture Partners Xii, Llc converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:01:33 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Financials

    Live finance-specific insights

    See more
    • Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

      Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placeb

      6/9/25 7:00:00 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    SEC Filings

    See more
    • SEC Form 8-K filed by Metsera Inc.

      8-K - Metsera, Inc. (0002040807) (Filer)

      6/9/25 7:04:25 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Metsera Inc.

      SCHEDULE 13G - Metsera, Inc. (0002040807) (Subject)

      6/3/25 4:30:15 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.

      SCHEDULE 13G/A - Metsera, Inc. (0002040807) (Subject)

      5/12/25 10:36:17 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Metsera with a new price target

      Guggenheim initiated coverage of Metsera with a rating of Buy and set a new price target of $56.00

      2/25/25 7:57:00 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Metsera with a new price target

      BofA Securities initiated coverage of Metsera with a rating of Buy and set a new price target of $38.00

      2/25/25 7:56:39 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Metsera

      Evercore ISI initiated coverage of Metsera with a rating of Outperform

      2/25/25 7:56:13 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care